In patients with dilated cardiomyopathy, the GH response to hexarelin was similar to that in age-matched controls.
In plain wordsIn patients with dilated cardiomyopathy, growth hormone rose after hexarelin about as much as in healthy controls.
- Peptide
- Hexarelin
- Outcome
- No significant changeGH response to hexarelin in dilated cardiomyopathy versus controls
- Study
n = 81
- Comparator
- Age-matched controls
- Outcome group
- Growth hormone and IGF-1 · Endocrine and hormones
- Studied dose
- 2.0 mu/kg · intravenousAs given in this study (human).
Measurements
- GH response hAUC0-120
- 611 mu/l/h
- dilated cardiomyopathy
- GH response hAUC0-120
- 535.4 mu/l/h
- controls
Source sentences
whereas that to HEX in DCM and CS was similar (611.0 +/- 437.5 vs. 535.4 +/- 302.8 mu/l/h; P = 0.95).
2 context sentences(design, population, supporting numbers)
b) the acute GH-response to GHRH (1.0 mu/kg i.v.) or hexarelin (HEX, 2.0 mu/kg i.v.), a peptidyl GH secretagogue (GHRP)
To clarify this point, we enrolled 39 patients with idiopathic or post-ischaemic DCM (36 M/3 F; age (mean +/- S.D.) 55.3 +/- 9.0 years; BMI: 25.3 +/- 3.2 kg/m2; New York Heart Association class (NYHA) I/2, II/19, III/15, IV/3) and 42 age-matched controls (CS, 38 M/4 F; age 56.0 +/- 7.8 years; BMI: 24.9 +/- 1.5 kg/m2).